• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性血细胞减少症、骨髓增生异常综合征或急性髓系白血病患者基因突变的独特种族特征。

Unique ethnic features of mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia.

机构信息

Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul.

Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul.

出版信息

Haematologica. 2022 Feb 1;107(2):510-518. doi: 10.3324/haematol.2020.270553.

DOI:10.3324/haematol.2020.270553
PMID:33626862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8804579/
Abstract

DDX41 mutations are associated with hematologic malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but the incidence in idiopathic cytopenia of undetermined significance (ICUS) is unknown. We investigated the incidence, genetic characteristics, and clinical features of DDX41 mutations in Korean patients with ICUS, MDS, or AML. We performed targeted deep sequencing of 61 genes including DDX41 in 457 patients with ICUS (n=75), MDS (n=210), or AML (n=172). Germline DDX41 mutations with causality were identified in 28 (6.1%) patients, of whom 27 (96.4%) had somatic mutations in the other position of DDX41. Germline origins of the DDX41 mutations were confirmed in all of the 11 patients in whom germline-based testing was performed. Of the germline DDX41 mutations, p.V152G (n=10) was most common, followed by p.Y259C (n=8), p.A500fs (n=6), and p.E7* (n=3). Compared with non-mutated patients, patients with a DDX41 mutation were more frequently male, older, had a normal karyotype, low leukocyte count, and hypocellular marrow at diagnosis. Three of the four ICUS patients with germline DDX41 mutations progressed to MDS. The incidence of DDX41 mutations in Korean patients was high and there was a distinct mutation pattern, in that p.V152G was a unique germline variant. ICUS harboring germline DDX41 mutations may be regarded as a hereditary myeloid neoplasm. Germline DDX41 mutations are not uncommon and should be explored when treating patients with myeloid malignancies.

摘要

DDX41 突变与包括骨髓增生异常综合征 (MDS) 和急性髓系白血病 (AML) 在内的血液系统恶性肿瘤有关,但在特发性细胞减少症伴意义未明的血细胞减少症 (ICUS) 中的发生率尚不清楚。我们研究了 DDX41 突变在韩国 IDCUS、MDS 或 AML 患者中的发生率、遗传特征和临床特征。我们对 457 例 IDCUS(n=75)、MDS(n=210)或 AML(n=172)患者的 61 个基因(包括 DDX41)进行了靶向深度测序。在 28 例(6.1%)患者中发现了具有因果关系的胚系 DDX41 突变,其中 27 例(96.4%)在 DDX41 的其他位置存在体细胞突变。在所有进行胚系检测的 11 例患者中均证实了 DDX41 突变的胚系起源。在胚系 DDX41 突变中,p.V152G(n=10)最为常见,其次是 p.Y259C(n=8)、p.A500fs(n=6)和 p.E7*(n=3)。与未突变患者相比,DDX41 突变患者更多为男性、年龄较大、核型正常、白细胞计数较低、骨髓细胞较少。4 例胚系 DDX41 突变的 IDCUS 患者中有 3 例进展为 MDS。韩国患者 DDX41 突变的发生率较高,且存在明显的突变模式,即 p.V152G 是一种独特的胚系变异。携带胚系 DDX41 突变的 IDCUS 可能被视为遗传性髓系肿瘤。胚系 DDX41 突变并不罕见,在治疗髓系恶性肿瘤患者时应进行探索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8a/8804579/ff21a64106e8/107510.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8a/8804579/b605ca32a8ac/107510.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8a/8804579/43c900006446/107510.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8a/8804579/ff21a64106e8/107510.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8a/8804579/b605ca32a8ac/107510.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8a/8804579/43c900006446/107510.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc8a/8804579/ff21a64106e8/107510.fig3.jpg

相似文献

1
Unique ethnic features of mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia.特发性血细胞减少症、骨髓增生异常综合征或急性髓系白血病患者基因突变的独特种族特征。
Haematologica. 2022 Feb 1;107(2):510-518. doi: 10.3324/haematol.2020.270553.
2
Peripheral Blood and Bone Marrow Findings in Treatment-Naive Patients With Cytopenia(s)/Myeloid Neoplasms Harboring Both a Germline and a Somatic DDX41 Mutation.治疗初治伴种系和体细胞 DDX41 突变的细胞减少症/髓系肿瘤患者的外周血和骨髓检查结果。
Appl Immunohistochem Mol Morphol. 2024 Sep 1;32(8):371-381. doi: 10.1097/PAI.0000000000001215. Epub 2024 Jul 24.
3
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.孤立型和共突变型 DDX41 突变髓系肿瘤患者的遗传特征和临床结局。
Blood Adv. 2022 Jan 25;6(2):528-532. doi: 10.1182/bloodadvances.2021005738.
4
Germline DDX41 mutations define a significant entity within adult MDS/AML patients.胚系 DDX41 突变定义了成年 MDS/AML 患者中的一个重要实体。
Blood. 2019 Oct 24;134(17):1441-1444. doi: 10.1182/blood.2019000909.
5
The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.胚系 DDX41 变异导致髓系肿瘤的遗传特征。
Blood. 2022 Aug 18;140(7):716-755. doi: 10.1182/blood.2021015135.
6
Novel DDX41 variants in Thai patients with myeloid neoplasms.泰国髓系肿瘤患者新型 DDX41 变异体。
Int J Hematol. 2020 Feb;111(2):241-246. doi: 10.1007/s12185-019-02770-3. Epub 2019 Nov 11.
7
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.胚系和体细胞 DDX41 缺陷及其对髓系肿瘤的影响。
Curr Hematol Malig Rep. 2022 Oct;17(5):113-120. doi: 10.1007/s11899-022-00667-3. Epub 2022 Jul 4.
8
The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.在诊断测序过程中发现的 DDX41 变异患者的临床和基因组特征。
Blood Adv. 2023 Dec 12;7(23):7346-7357. doi: 10.1182/bloodadvances.2023011389.
9
DDX41-related myeloid neoplasia.与DDX41相关的髓系肿瘤
Semin Hematol. 2017 Apr;54(2):94-97. doi: 10.1053/j.seminhematol.2017.04.007. Epub 2017 Apr 21.
10
Myeloid neoplasms with germline DDX41 mutation.伴有种系DDX41突变的髓系肿瘤
Int J Hematol. 2017 Aug;106(2):163-174. doi: 10.1007/s12185-017-2260-y. Epub 2017 May 25.

引用本文的文献

1
Identifying lncRNA-Protein Interactions in Hematopoietic Progenitor Cells by Hybridization Capture and Mass Spectrometry.通过杂交捕获和质谱法鉴定造血祖细胞中的长链非编码RNA-蛋白质相互作用
J Proteome Res. 2025 Aug 1. doi: 10.1021/acs.jproteome.5c00334.
2
Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.髓系肿瘤中DDX41突变的临床病理及预后意义:一项系统综述和荟萃分析
Ann Hematol. 2025 Apr 21. doi: 10.1007/s00277-025-06278-1.
3
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome.

本文引用的文献

1
Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).胚系转录因子突变(RUNX1、GATA2、CEBPA)患者的继发性白血病。
Blood. 2020 Jul 2;136(1):24-35. doi: 10.1182/blood.2019000937.
2
Novel DDX41 variants in Thai patients with myeloid neoplasms.泰国髓系肿瘤患者新型 DDX41 变异体。
Int J Hematol. 2020 Feb;111(2):241-246. doi: 10.1007/s12185-019-02770-3. Epub 2019 Nov 11.
3
Germline DDX41 mutations define a significant entity within adult MDS/AML patients.胚系 DDX41 突变定义了成年 MDS/AML 患者中的一个重要实体。
DDX41突变种系易患综合征患者血细胞减少症和体细胞变异的患病率
Br J Haematol. 2025 Apr;206(4):1109-1120. doi: 10.1111/bjh.20018. Epub 2025 Mar 4.
4
Myelodysplastic syndrome with dual germline RUNX1 and DDX41 variants: a rare genetic predisposition case.伴有双胚系RUNX1和DDX41变异的骨髓增生异常综合征:1例罕见的遗传易感性病例。
Fam Cancer. 2025 Jan 31;24(1):20. doi: 10.1007/s10689-025-00443-1.
5
Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding.髓系肿瘤中的种系DDX41突变:当前的临床与分子认识
Curr Opin Hematol. 2025 Mar 1;32(2):67-76. doi: 10.1097/MOH.0000000000000854. Epub 2024 Nov 20.
6
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With a Germline Mutation.异基因造血干细胞移植治疗伴有种系突变的急性髓系白血病
Case Rep Hematol. 2024 Nov 1;2024:4611649. doi: 10.1155/2024/4611649. eCollection 2024.
7
Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts.基于基因组优先确定八个种系髓系恶性肿瘤易感基因的患病率和外显率:一项基于两个群体队列的研究
Leukemia. 2025 Feb;39(2):400-411. doi: 10.1038/s41375-024-02436-y. Epub 2024 Nov 6.
8
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation.YTHDC1 与 METTL3/METTL14 结合亲和力受损导致 DDX41 突变的骨髓增生异常肿瘤中 R 环积累。
Leukemia. 2024 Jun;38(6):1353-1364. doi: 10.1038/s41375-024-02228-4. Epub 2024 Mar 21.
9
Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines.使用 ACMG/AMP 指南评估胚系 DDX41 变异在血液系统肿瘤中的致病潜能。
Int J Hematol. 2024 May;119(5):552-563. doi: 10.1007/s12185-024-03728-w. Epub 2024 Mar 16.
10
Genomic testing for germline predisposition to hematologic malignancies.血液系统恶性肿瘤种系易感性的基因组检测。
Blood Res. 2024 Mar 8;59(1):12. doi: 10.1007/s44313-024-00012-y.
Blood. 2019 Oct 24;134(17):1441-1444. doi: 10.1182/blood.2019000909.
4
Hereditary myeloid malignancies.遗传性髓系恶性肿瘤。
Best Pract Res Clin Haematol. 2019 Jun;32(2):163-176. doi: 10.1016/j.beha.2019.05.001. Epub 2019 May 3.
5
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.髓系肿瘤中的 DDX41 突变与男性性别、TP53 突变和高危疾病相关。
Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7.
6
Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia.一名患有成人起病的无发育异常的母细胞增多性髓系肿瘤患者的新型种系错义DDX41变异体。
Leuk Lymphoma. 2019 May;60(5):1337-1339. doi: 10.1080/10428194.2018.1522443. Epub 2018 Nov 8.
7
Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.利用基于下一代测序的白血病预后 panels 提高遗传性血液恶性肿瘤易感性患者的检出率。
Cancer. 2018 Jul 1;124(13):2704-2713. doi: 10.1002/cncr.31331. Epub 2018 Apr 6.
8
Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.用于最佳检测骨髓增生异常综合征体细胞变异的生殖系组织。
Blood. 2018 May 24;131(21):2402-2405. doi: 10.1182/blood-2018-01-827881. Epub 2018 Apr 16.
9
Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.预后肿瘤测序panel 常能鉴定与遗传性血液恶性肿瘤相关的胚系变异。
Blood Adv. 2018 Jan 23;2(2):146-150. doi: 10.1182/bloodadvances.2017013037.
10
DDX41-related myeloid neoplasia.与DDX41相关的髓系肿瘤
Semin Hematol. 2017 Apr;54(2):94-97. doi: 10.1053/j.seminhematol.2017.04.007. Epub 2017 Apr 21.